Thalassemia Clinical Trial
Official title:
Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients
Verified date | May 2012 |
Source | Mahidol University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the efficacy of antioxidant cocktails on the alleviation of oxidative stress and iron overload in beta-thalassemia/Hb E patients.
Status | Completed |
Enrollment | 60 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. age between 18-50 years 2. hemoglobin level between 6-9 g/dL during screen visit 3. WHO performance status grade 0-2 4. signed in informed consents prior to the study entry. Exclusion Criteria: 1. receiving iron chelator and blood transfusion. 2. pregnancy or breastfeeding 3. receiving other drugs except folic acid at least 30 days before study. |
Country | Name | City | State |
---|---|---|---|
Thailand | Department of Biochemistry , Faculty of Medicine Siriraj Hospital, Mahidol university | Bangkoknoi | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Mahidol University | ChaingMai University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Malonyldiadehyde (MDA) | Lipid peroxidation will be assayed by measuring the formation of malonyldialdehyde (MDA). The formation of MDA on red blood cell will be exposed by hydrogen peroxide. Then, MDA will be extracted by trichloroacetic acid (TCA) and will be reacted with thiobarbituric acid (TBA) in boiling condition to MDA-TBAR complex. This complex will be given pink color and measuring at 532 and 600 nm | 1 year after treatment with antioxidant cocktail. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT04614779 -
Long-term Clinical Study of CN128 in Thalassemia Patients
|
Phase 2 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT02995707 -
The Effective and Safety of Thalidomide in NTDT
|
Phase 2 | |
Active, not recruiting |
NCT01935661 -
A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
|
||
Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00901199 -
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
|
Phase 2 | |
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05508932 -
Atrial Fibrillation in Beta-Thalassemia
|
||
Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Completed |
NCT03117192 -
Zinc Supplementation on Cellular Immunity in Thalassemia Major
|
Phase 4 | |
Completed |
NCT03095326 -
Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia
|
Phase 4 | |
Completed |
NCT01443312 -
Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
|
||
Completed |
NCT00744692 -
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
|
Phase 1 | |
Completed |
NCT00235391 -
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
|
Phase 3 | |
Not yet recruiting |
NCT06058260 -
Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
|
||
Completed |
NCT05529550 -
Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
|
||
Completed |
NCT04582110 -
The Role of OCTA in Patients Affected by Beta Thalassemia
|
||
Recruiting |
NCT06213402 -
RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
|